Articles tagged with Breast Cancer Cells
Researchers at UT Health San Antonio have identified a novel way to kill cancers caused by inherited BRCA1 mutations. Adding back microRNA 223-3p forces BRCA1-mutant cancer cells to die, offering a potential treatment for inherited breast and ovarian cancer.
Researchers created a deformable nanolipogel-based delivery system for CRISPR knockout of oncogene Lcn2, reducing tumor growth by 77% in human and mouse models. The delivery method shows promise as a precise therapeutic tool for treating triple-negative breast cancer.
Researchers are conducting a phase 1 clinical trial using CAR-T cells, which have been shown to attack and kill cancers. The goal is to learn more about how these super-powered immune cells interact with solid tumors to develop effective treatments for various types of cancer.
Researchers at Ohio State University found that low-intensity electromagnetic fields reduce the ability of specific breast cancer cells to migrate and spread. The study used a lab model to mimic the body environment and discovered that certain drug therapies can enhance the effects of electromagnetic fields on blocking cancer cell meta...
Researchers at Worcester Polytechnic Institute developed a chip made of carbon nanotubes that captures circulating tumor cells (CTCs) with far greater sensitivity than existing technologies. The device can detect early-stage tumors, predict the course of a cancer, and monitor the effects of therapy.
A new mathematical model reveals that breast cancer cells can change shape to facilitate spreading to other parts of the body. The researchers also found that these cells can cross the endothelium barrier with greater ease, which is a critical step in metastasis.
A new study found that Slug promotes breast stem cell health by repairing DNA damage, and its deficiency is linked to increased DNA damage and decreased stem cell activity in both young and aged breast tissue. This suggests that Slug functions as a safeguard against age-related decline of breast stem cell function.
A recent study by Chiaki Takahashi at Kanazawa University discovered that the cancer gene RB promotes tumor growth by altering the tumor microenvironment (TME). The TME changes enable the accumulation of immunosuppressive cells, which overpower the body's natural defense system.
Researchers at the University of Akron have developed 3D tumor models that more accurately replicate human tumors than traditional 2D cultures. These models are being used to test new drugs and understand the drivers of triple-negative breast cancer, a type of cancer with limited treatment options.
A team of UCI researchers, led by Kai Kessenbrock and Devon Lawson, will compile a high-resolution atlas of human breast tissue cell types and states. The project aims to document the intricate complexity of normal tissue homeostasis and disease, leading to new insights into breast cancer origins.
Researchers discovered that DBC1 protein helps regulate normal anti-cancer functions and that restoring its expression can prevent cancer development and increase therapy effectiveness. The study found that maintaining DBC1 levels in cancer cells exposed to certain drugs triggers a substantially increased response to treatment.
A pre-clinical study led by Duke University Medical Center identified an enzyme in cells involved in regulating breast cancer growth and spread. Inhibiting this enzyme's activity allowed T-cells to mount an immune attack on cancer cells, potentially improving treatment outcomes for breast cancer patients.
Researchers identified a genetic switch in breast cancer cells that boosts Keratin-80 production, making cells more rigid and prone to invade nearby tissues. The study suggests targeting this switch with a different drug could help reverse resistance and prevent cancer spread.
A new laboratory test could accurately predict which breast cancers are likely to spread and help clinicians select optimal treatments. The test, called Microfluidic Assay for quantification of Cell Invasion (MAqCI), assesses three key features of metastasis in cancer cells.
A new blood biopsy technique allows for comprehensive genetic profiling of cancer cells, capturing variation among cells within a single patient. This improves treatment monitoring and targeting by identifying genes active in cancer cells and tracking their response to therapy.
Researchers discovered a type of bone cell that can subdue cancer cells, slowing their growth in breast cancer patients. Osteoblasts release factors that halt cancer cell growth, restoring production of the cell-cycle checkpoint protein p21 and putting cancer cells to sleep.
A Brazilian research team developed a new strategy to slow the growth of triple negative breast cancer cells by cutting them off from two major food sources: fatty acids and glutamine. The study found that inhibiting both metabolic pathways slowed the growth and migration of resistant TNBC cells.
Researchers at Hiroshima University found that high levels of TIMP-1 increase liposarcoma tumor cell spread and aggression, while high TIMP-4 levels decrease migration and cell proliferation. This understanding can lead to new therapeutics and diagnostic methods for liposarcoma.
Researchers at Stanford University School of Medicine have developed a synthetic biology approach that targets cancer cells with customizable treatments. The RASER system uses two proteins to kill only overly active cancer cells while sparing healthy ones, promising a more targeted and effective treatment.
Researchers at Cornell University discovered a link between diabetes and increased risk of metastatic cancer, attributed to the glycation of collagen matrices. Elevated blood sugar levels lead to structural changes in collagen fibers, facilitating cancer cell movement through the body.
Cancer cells use PD-L1 to evade immune surveillance and resist chemotherapy and radiation therapy. Researchers propose using an antibody that disrupts PD-L1's internal function to make cancer cells more sensitive to treatment.
Researchers have developed new Cryo-Chip substrates that improve contrast and specimen retention in cryo-electron microscopy (cryo-EM) imaging. These advancements enable faster data acquisition, leading to more efficient analysis of macromolecules in various biological systems.
Researchers discovered that gasdermin E forms holes in cell membranes, leading to cell death and suppressing tumor growth. The protein's expression is lower in many types of cancer, suggesting it may be a useful target for improving cancer therapy.
Researchers identified UNC45A as a key player in cancer cell proliferation and tumor growth. Inhibiting UNC45A was found to decrease cancer cell proliferation and cause mitotic catastrophe, leading to cell death.
A new study found that transfer RNA-derived fragments play a significant role in gene expression, differing by cancer type and sex of the patient. The mitochondrion is involved in these interactions, particularly with repetitive elements.
A new biomarker, TP53INP2, has been identified as a potential marker for personalized cancer treatments. This protein increases the sensitivity of cancer cells to death signals, such as TRAIL, enhancing the efficacy of chemotherapy treatments.
Researchers used mass cytometry to analyze millions of cancer and immune cells from 140 patients, discovering unique cellular compositions in each tumor. The study found that aggressive tumors are dominated by a single type of cell, while immune therapy may work for previously unsuitable breast cancer patients.
Scientists at Hebrew University create decoy molecules that trick RNA-binding proteins into binding with them, inhibiting their cancer-promoting activity. The technology has shown promise in slowing or stopping the growth of brain and breast cancer cells in mice.
Scientists discovered a set of genes expressed in high levels in breast cancer tumors linked to aggressive types and shorter patient survival. The findings offer clues for diagnosis, prognosis, and potential drug discovery.
Scientists have found that successful removal of breast cancer tumors triggers a strong immune response, which clears disseminated tumor cells from lymph nodes and organs. In contrast, leaving behind primary tumor cells supports tumor growth and metastasis.
Breast cancer cells exploit the FGFR4 receptor to regulate growth and prevent programmed cell death. Targeting this vulnerability with combination therapies shows promise for improving treatment outcomes.
Researchers at UNIGE and UNIL discover clofazimine's efficacy in stopping triple negative breast cancer progression by blocking Wnt cell signaling pathway. The study highlights the need to re-examine existing drugs for potential targeted therapy.
Breast cancer cells are inherently changeable, morphing from one cell type to another at the molecular level. This feature may promote resistance to certain therapies. The research provides new insights into how cancer cells develop and evolve within tumours.
A new thixogel called CNF hydrogel has been developed by SUTD researchers, offering improved cell encapsulation and delivery. The hydrogel combines the benefits of both solid and liquid forms, providing a protective environment for cells while conforming to host tissue geometry.
Researchers at Vanderbilt University discovered that cancer cells use leader-follower behavior to establish new tumor sites, expending more energy in the process. This finding has significant implications for fighting cancer, particularly in understanding mechanisms of metastasis and developing new therapies.
Researchers at McMaster University have developed a method to create artificial tumours using magnetic 3D printing, enabling faster and more affordable testing of new treatments. The technique uses magnets to concentrate human cells in a predetermined area, forming 3D cell clusters that mimic human tissues.
Researchers developed a nano-bomb targeting POLR2A, a viable target for treating triple negative breast cancer. The nano-bomb kills only cancerous cells while leaving healthy cells alive.
Researchers at the University of North Carolina Health Care discovered the enzyme USP21 promotes basal-like breast cancer proliferation and is upregulated in patient tumors. Targeting USP21 may sensitize cancer cells to existing therapies.
Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) is a distinct form of cancer linked to textured breast implants. Clear guidelines formalize treatment strategy, recommending surgical techniques like stepwise en bloc resection for complete oncologic resection and removal of involved lymph nodes.
A new study by Prof. Sarah-Maria Fendt and her PhD student Ilaria Elia found that breast cancer cells require pyruvate to reshape the lung environment and create a pro-tumor niche. In contrast, normal bone cells rely on glutamine for this process.
Differential H3K27AC marks were identified at enhancer regions of genes including c-MYC, MED1, OCT-4, NANOG, and SOX2. Alteration in transcription and enhancer landscape occurs during disease progression, offering a potent therapeutic mark for targeting cancer cells.
Researchers outline a targeted therapeutic strategy to treat triple-negative breast cancer using POLR2A gene targeting. The proposed approach utilizes nanotechnology-based precision-targeting to kill TNBC cells while sparing normal cells, offering hope for improved treatment options.
A new study from the University of Copenhagen has identified a key mechanism behind the repair of human DNA damage, which can lead to cancer. The researchers have discovered a protein called BARD1 that acts like a 'scanner' to launch the flawless DNA repair system.
Researchers at the University of Illinois have developed a technology platform that digitally counts growth factor binding in individual cells. This breakthrough allows for direct cause-and-effect relationships between growth factors and cell behavior, leading to a better understanding of cell signaling and resistance to cancer treatme...
A new study reveals that chronic stress promotes breast cancer growth and spread by activating a biochemical pathway involving the stress hormone epinephrine. Vitamin C has been identified as a potential therapeutic agent to target this pathway, potentially offering new hope for patients undergoing chronic stress.
A new study uses cellular barcoding to pinpoint cells responsible for breast cancer's spread, shedding light on how chemotherapy works and identifying targets for new treatments. Researchers hope to develop targeted therapies by understanding the molecular basis of cancer cell behavior.
Researchers at the University of California San Diego discovered that breast tissue stiffening triggers multiple pathways to promote cancer cell formation. The study, published in PNAS, found that a subpopulation of mammary cells do not respond to stiffening, potentially leading to fewer or smaller primary tumors.
Researchers discovered how a metallodrug reaches cancer cells and attacks them efficiently. The molecule penetrates the cell membrane and targets essential organelles, leading to anticancer activity.
Breast cancer cells can shift between two forms of the cell surface molecule CD44, CD44s and CD44v, with different properties and behaviors. Cancer cells expressing mainly CD44s have increased metastatic behavior and resistance to therapy, while those expressing CD44v present increased cell proliferation.
Researchers at Kanazawa University have discovered a critical signaling pathway that drives the proliferation of cancer stem cells in breast cancer. The pathway, involving Semaphorin 3 and MICAL3 proteins, is targeted by inhibiting these proteins to reduce breast-cancer stem-like cells.
Researchers at Brigham and Women's Hospital have discovered two new genetic targets, APEX2 and FEN1, which show promise as potential treatments for hereditary breast and ovarian cancers. The study's findings suggest that inhibiting these enzymes could complement existing Parp inhibitors and address drug resistance in BRCA-driven cancer.
The foundation awarded grants to nine early-career scientists working on novel approaches to fighting cancer. The recipients will receive up to four years of funding to explore their projects, which include gene editing technology CRISPR and single cell sequencing techniques.
Researchers at the University of Basel have developed a novel differentiation therapy that converts breast cancer cells into fat cells, impeding the formation of metastases in mice. The therapy combines two active substances, Rosiglitazone and Trametinib, to suppress tumor growth and spread.
Researchers successfully converted invasive breast cancer cells in mice into harmless fat cells using two FDA-approved drugs, suppressing tumor growth and metastasis. This breakthrough could potentially deplete a tumor's ability to fight off conventional chemotherapy.
Basel researchers identified a substance that prevents the formation of metastases by dissociating circulating tumor cell clusters and reversing epigenetic changes. This approach targets key aspects of metastasis seeding, including proliferation and tissue-forming capabilities.
The discovery of protein DEX-1 in the roundworm C. elegans sheds light on the molecular trigger for structural remodeling in response to stress, allowing animals to better withstand challenging conditions. This research has implications for understanding nematode biology and its impact on parasitic species affecting crops.
Researchers discovered that protrusions on cells trigger Ras-ERK activity, a frequently mutated cancer pathway. This finding could lead to new targets for cancer therapeutics and potentially offer alternative approaches to modulating the pathway's activity.
Researchers found a novel time-keeping mechanism within liver cells that contributes to disease development when its natural rhythm is disrupted. The study suggests that the circadian clock modulates HNF4A's classical functions, providing a potential explanation for diseases such as diabetes and cancers.
A Syracuse University physicist has developed tiny sensors that can detect and analyze protein-protein interactions in blood serum, which could lead to improved cancer detection. The technology, known as nanobiosensors, uses a nanopore to measure changes in electric current when proteins are present.
Researchers at Tel Aviv University discovered that breast cancer tumors recruit stromal cells from bone marrow, boosting tumor cell proliferation and blood vessel formation. This finding highlights the potential for targeting these cells with novel therapies to treat the disease.